{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T16:07:04Z","timestamp":1789056424066,"version":"build-2803163510"},"reference-count":61,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100024091","name":"Orchard Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024091","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019256","name":"NIHR Great Ormond Street Hospital Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019256","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000765","name":"University College London","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000765","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003784","name":"Great Ormond Street Hospital for Children","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003784","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Advances"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.omta.2026.201824","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T15:23:13Z","timestamp":1785424993000},"page":"201824","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["GAA engineered to improve cellular uptake enhances correction in a preclinical hematopoietic stem cell gene therapy model of Pompe disease"],"prefix":"10.1016","volume":"34","author":[{"given":"Slawomir","family":"Wantuch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Tuske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Benedetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nickita","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon J.","family":"Brudvig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung","family":"Do","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell","family":"Gotschall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessie","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna B.","family":"Gaspar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Recchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Heal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler B.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fulvio","family":"Mavilio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2568-9126","authenticated-orcid":false,"given":"Pervinder","family":"Sagoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill M.","family":"Weimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Bobby","family":"Gaspar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omta.2026.201824_bib1","doi-asserted-by":"crossref","first-page":"15856","DOI":"10.18632\/aging.103794","article-title":"Pompe disease: pathogenesis, molecular genetics and diagnosis","volume":"12","author":"Taverna","year":"2020","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.omta.2026.201824_bib2","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.omtm.2022.10.017","article-title":"Screening chimeric GAA variants in preclinical study results in hematopoietic stem cell gene therapy candidate vectors for Pompe disease","volume":"27","author":"Dogan","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omta.2026.201824_bib3","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3389\/fnagi.2014.00177","article-title":"Pompe disease: from pathophysiology to therapy and back again","volume":"6","author":"Lim","year":"2014","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.omta.2026.201824_bib4","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/mt.2009.37","article-title":"Glycoengineered acid alpha-glucosidase with improved efficacy at correcting the metabolic aberrations and motor function deficits in a mouse model of Pompe disease","volume":"17","author":"Zhu","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201824_bib5","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.omtm.2022.09.010","article-title":"IGF2-tagging of GAA promotes full correction of murine Pompe disease at a clinically relevant dosage of lentiviral gene therapy","volume":"27","author":"Liang","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omta.2026.201824_bib6","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s13023-017-0693-2","article-title":"A study on the safety and efficacy of reveglucosidase alfa in patients with late-onset Pompe disease","volume":"12","author":"Byrne","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.omta.2026.201824_bib7","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/GIM.0b013e3182174703","article-title":"The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease","volume":"13","author":"Banugaria","year":"2011","journal-title":"Genet. Med."},{"key":"10.1016\/j.omta.2026.201824_bib8","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ymgme.2017.10.005","article-title":"Neuroimaging findings in infantile Pompe patients treated with enzyme replacement therapy","volume":"123","author":"McIntosh","year":"2018","journal-title":"Mol. Genet. Metabol."},{"key":"10.1016\/j.omta.2026.201824_bib9","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1182\/blood-2013-01-306647","article-title":"Immune responses to AAV vectors: overcoming barriers to successful gene therapy","volume":"122","author":"Mingozzi","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.omta.2026.201824_bib10","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1089\/hum.2019.109","article-title":"Gene Therapy for Pompe Disease: The Time is now","volume":"30","author":"Colella","year":"2019","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omta.2026.201824_bib11","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.omtm.2018.11.002","article-title":"AAV Gene Transfer with Tandem Promoter Design Prevents Anti-transgene Immunity and Provides Persistent Efficacy in Neonate Pompe Mice","volume":"12","author":"Colella","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omta.2026.201824_bib12","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.omtm.2023.01.003","article-title":"Persistent hematopoietic polyclonality after lentivirus-mediated gene therapy for Fabry disease","volume":"28","author":"Saleh","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omta.2026.201824_bib13","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S0140-6736(21)02017-1","article-title":"Lentiviral haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy: long-term results from a non-randomised, open-label, phase 1\/2 trial and expanded access","volume":"399","author":"Fumagalli","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.omta.2026.201824_bib14","doi-asserted-by":"crossref","first-page":"5130","DOI":"10.1182\/blood-2010-04-278234","article-title":"Gene therapy augments the efficacy of hematopoietic cell transplantation and fully corrects mucopolysaccharidosis type I phenotype in the mouse model","volume":"116","author":"Visigalli","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.omta.2026.201824_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurot.2024.e00440","article-title":"Hematopoietic stem cell gene therapy to halt neurodegeneration","volume":"21","author":"Biffi","year":"2024","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.omta.2026.201824_bib16","doi-asserted-by":"crossref","first-page":"15018","DOI":"10.1073\/pnas.1205858109","article-title":"Brain conditioning is instrumental for successful microglia reconstitution following hematopoietic stem cell transplantation","volume":"109","author":"Capotondo","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omta.2026.201824_bib17","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.omtm.2020.07.001","article-title":"Lentiviral Hematopoietic Stem Cell Gene Therapy Rescues Clinical Phenotypes in a Murine Model of Pompe Disease","volume":"18","author":"Piras","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omta.2026.201824_bib18","doi-asserted-by":"crossref","first-page":"3847","DOI":"10.1016\/j.ymthe.2024.09.024","article-title":"Preclinical lentiviral hematopoietic stem cell gene therapy corrects Pompe disease-related muscle and neurological manifestations","volume":"32","author":"Yoon","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201824_bib19","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.omtm.2020.04.023","article-title":"Lentiviral Hematopoietic Stem Cell Gene Therapy Corrects Murine Pompe Disease","volume":"17","author":"Stok","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omta.2026.201824_bib20","doi-asserted-by":"crossref","first-page":"5329","DOI":"10.1182\/blood-2009-11-252874","article-title":"Lentiviral gene therapy of murine hematopoietic stem cells ameliorates the Pompe disease phenotype","volume":"115","author":"van Til","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.omta.2026.201824_bib21","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1073\/pnas.0308728100","article-title":"Glycosylation-independent targeting enhances enzyme delivery to lysosomes and decreases storage in mucopolysaccharidosis type VII mice","volume":"101","author":"LeBowitz","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omta.2026.201824_bib22","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1042\/bj2930713","article-title":"Insulin-like growth factor (IGF)-II binding to IGF-binding proteins and IGF receptors is modified by deletion of the N-terminal hexapeptide or substitution of arginine for glutamate-6 in IGF-II","volume":"293","author":"Francis","year":"1993","journal-title":"Biochem. J."},{"key":"10.1016\/j.omta.2026.201824_bib23","doi-asserted-by":"crossref","first-page":"20626","DOI":"10.1016\/S0021-9258(18)54755-4","article-title":"The design, expression, and characterization of human insulin-like growth factor II (IGF-II) mutants specific for either the IGF-II\/cation-independent mannose 6-phosphate receptor or IGF-I receptor","volume":"266","author":"Sakano","year":"1991","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.omta.2026.201824_bib24","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1006\/scdb.1999.0318","article-title":"Role and regulation of the ER chaperone BiP","volume":"10","author":"Gething","year":"1999","journal-title":"Semin. Cell Dev. Biol."},{"key":"10.1016\/j.omta.2026.201824_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.100769","article-title":"Endolysosomal N-glycan processing is critical to attain the most active form of the enzyme acid alpha-glucosidase","volume":"296","author":"Selvan","year":"2021","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.omta.2026.201824_bib26","doi-asserted-by":"crossref","first-page":"9873","DOI":"10.1128\/JVI.72.12.9873-9880.1998","article-title":"Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery","volume":"72","author":"Zufferey","year":"1998","journal-title":"J. Virol."},{"key":"10.1016\/j.omta.2026.201824_bib27","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1074\/jbc.M112.438663","article-title":"Glycosylation-independent lysosomal targeting of acid alpha-glucosidase enhances muscle glycogen clearance in pompe mice","volume":"288","author":"Maga","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.omta.2026.201824_bib28","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21062256","article-title":"The Respiratory Phenotype of Pompe Disease Mouse Models","volume":"21","author":"Fusco","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omta.2026.201824_bib29","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1089\/hum.2019.190","article-title":"Gene-Based Approaches to Inherited Neurometabolic Diseases","volume":"30","author":"Poletti","year":"2019","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omta.2026.201824_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.braindev.2025.104384","article-title":"Hematopoietic stem cell gene therapy of neurometabolic lysosomal storage diseases","volume":"47","author":"Consiglieri","year":"2025","journal-title":"Brain Dev."},{"key":"10.1016\/j.omta.2026.201824_bib31","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1038\/s41436-020-0878-2","article-title":"The multiple faces of urinary glucose tetrasaccharide as biomarker for patients with hepatic glycogen storage diseases","volume":"22","author":"Heiner-Fokkema","year":"2020","journal-title":"Genet. Med."},{"key":"10.1016\/j.omta.2026.201824_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2024.108590","article-title":"Pompe disease: Unmet needs and emerging therapies","volume":"143","author":"George","year":"2024","journal-title":"Mol. Genet. Metabol."},{"key":"10.1016\/j.omta.2026.201824_bib33","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s11940-022-00736-1","article-title":"Pompe Disease: a Clinical, Diagnostic, and Therapeutic Overview","volume":"24","author":"Stevens","year":"2022","journal-title":"Curr. Treat. Options Neurol."},{"key":"10.1016\/j.omta.2026.201824_bib34","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.omtm.2019.08.009","article-title":"AAV Gene Therapy Utilizing Glycosylation-Independent Lysosomal Targeting Tagged GAA in the Hypoglossal Motor System of Pompe Mice","volume":"15","author":"Doyle","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omta.2026.201824_bib35","doi-asserted-by":"crossref","first-page":"9268","DOI":"10.1016\/S0021-9258(18)67649-5","article-title":"Insulin-like growth factor II binding to the type I somatomedin receptor. Evidence for two high affinity binding sites","volume":"261","author":"Casella","year":"1986","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.omta.2026.201824_bib36","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/jgm.1305","article-title":"Partial phenotypic correction and immune tolerance induction to enzyme replacement therapy after hematopoietic stem cell gene transfer of alpha-glucosidase in Pompe disease","volume":"11","author":"Douillard-Guilloux","year":"2009","journal-title":"J. Gene Med."},{"key":"10.1016\/j.omta.2026.201824_bib37","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1111\/ene.15894","article-title":"Long-term follow-up of 64 children with classical infantile-onset Pompe disease since 2004: A French real-life observational study","volume":"30","author":"Tardieu","year":"2023","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.omta.2026.201824_bib38","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa2106596","article-title":"Hematopoietic Stem- and Progenitor-Cell Gene Therapy for Hurler Syndrome","volume":"385","author":"Gentner","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omta.2026.201824_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.imlet.2024.106931","article-title":"Gene therapy strategies for RAG1 deficiency: Challenges and breakthroughs","volume":"270","author":"Gilioli","year":"2024","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.omta.2026.201824_bib40","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/sj.mt.6300030","article-title":"Murine retroviral but not human cellular promoters induce in vivo erythroid-specific deregulation that can be partially prevented by insulators","volume":"15","author":"Robert-Richard","year":"2007","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201824_bib41","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1038\/mt.2016.55","article-title":"Evaluating the Safety of Retroviral Vectors Based on Insertional Oncogene Activation and Blocked Differentiation in Cultured Thymocytes","volume":"24","author":"Zhou","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201824_bib42","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa2405541","article-title":"Hematologic Cancer after Gene Therapy for Cerebral Adrenoleukodystrophy","volume":"391","author":"Duncan","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omta.2026.201824_bib43","first-page":"346","article-title":"A retrospective cohort study of Libmeldy (atidarsagene autotemcel) for MLD: What we have accomplished and what opportunities lie ahead","volume":"64","author":"Horgan","year":"2023","journal-title":"JIMD Rep."},{"key":"10.1016\/j.omta.2026.201824_bib44","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.ymthe.2006.08.009","article-title":"Autophagy and mistargeting of therapeutic enzyme in skeletal muscle in Pompe disease","volume":"14","author":"Fukuda","year":"2006","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201824_bib45","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.ymgme.2005.03.010","article-title":"Glucose tetrasaccharide as a biomarker for monitoring the therapeutic response to enzyme replacement therapy for Pompe disease","volume":"85","author":"An","year":"2005","journal-title":"Mol. Genet. Metabol."},{"key":"10.1016\/j.omta.2026.201824_bib46","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.ncl.2014.04.010","article-title":"Pompe disease: literature review and case series","volume":"32","author":"Dasouki","year":"2014","journal-title":"Neurol. Clin."},{"key":"10.1016\/j.omta.2026.201824_bib47","doi-asserted-by":"crossref","DOI":"10.3390\/ph16091199","article-title":"Improved Enzyme Replacement Therapy with Cipaglucosidase Alfa\/Miglustat in Infantile Pompe Disease","volume":"16","author":"Fiege","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.omta.2026.201824_bib48","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41392-023-01481-w","article-title":"The blood-brain barrier: structure, regulation, and drug delivery","volume":"8","author":"Wu","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.omta.2026.201824_bib49","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1212\/WNL.0000000000002523","article-title":"Cognitive decline in classic infantile Pompe disease: An underacknowledged challenge","volume":"86","author":"Ebbink","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.omta.2026.201824_bib50","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3389\/fnins.2015.00417","article-title":"Neuroinflammatory paradigms in lysosomal storage diseases","volume":"9","author":"Bosch","year":"2015","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.omta.2026.201824_bib51","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/jimd.12736","article-title":"Long term survival in patients with classic infantile Pompe disease reveals a spectrum with progressive brain abnormalities and changes in cognitive functioning","volume":"47","author":"van den Dorpel","year":"2024","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.omta.2026.201824_bib52","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1126\/science.3278379","article-title":"Donor-derived cells in the central nervous system of twitcher mice after bone marrow transplantation","volume":"239","author":"Hoogerbrugge","year":"1988","journal-title":"Science"},{"key":"10.1016\/j.omta.2026.201824_bib53","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.bbmt.2015.02.011","article-title":"Hematopoietic cell transplantation for mucopolysaccharidosis patients is safe and effective: results after implementation of international guidelines","volume":"21","author":"Aldenhoven","year":"2015","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.omta.2026.201824_bib54","doi-asserted-by":"crossref","DOI":"10.3390\/cells10051077","article-title":"Combining Mobilizing Agents with Busulfan to Reduce Chemotherapy-Based Conditioning for Hematopoietic Stem Cell Transplantation","volume":"10","author":"Garcia-Perez","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.omta.2026.201824_bib55","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2022.965089","article-title":"Delivering gene therapy for mucopolysaccharide diseases","volume":"9","author":"Wood","year":"2022","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.omta.2026.201824_bib56","unstructured":"EMA. Available from: https:\/\/efim.org\/node\/147752."},{"key":"10.1016\/j.omta.2026.201824_bib57","unstructured":"FDA. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-gene-therapy-children-metachromatic-leukodystrophy."},{"key":"10.1016\/j.omta.2026.201824_bib58","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-75300-9","article-title":"Lysosomal enzyme binding to the cation-independent mannose 6-phosphate receptor is regulated allosterically by insulin-like growth factor 2","volume":"14","author":"Bohnsack","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omta.2026.201824_bib59","doi-asserted-by":"crossref","DOI":"10.1038\/mtm.2016.17","article-title":"Production of lentiviral vectors","volume":"3","author":"Merten","year":"2016","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omta.2026.201824_bib60","unstructured":"ASPA. Available from: https:\/\/www.legislation.gov.uk\/ukpga\/1986\/14\/contents."},{"key":"10.1016\/j.omta.2026.201824_bib61","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s10545-011-9360-2","article-title":"Urine analysis of glucose tetrasaccharide by HPLC; a useful marker for the investigation of patients with Pompe and other glycogen storage diseases","volume":"35","author":"Manwaring","year":"2012","journal-title":"J. Inherit. Metab. Dis."}],"container-title":["Molecular Therapy Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3117387X2600159X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3117387X2600159X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T15:15:33Z","timestamp":1789053333000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S3117387X2600159X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":61,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S3117387X2600159X"],"URL":"https:\/\/doi.org\/10.1016\/j.omta.2026.201824","relation":{},"ISSN":["3117-387X"],"issn-type":[{"value":"3117-387X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"GAA engineered to improve cellular uptake enhances correction in a preclinical hematopoietic stem cell gene therapy model of Pompe disease","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omta.2026.201824","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"201824"}}